Literature DB >> 10359817

P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

W Tao1, A J Levine.   

Abstract

The INK4a-ARF locus encodes two distinct tumor suppressors, p16(INK4a) and p19(ARF). Whereas p16(INK4a) restrains cell growth through preventing phosphorylation of the retinoblastoma protein, p19(ARF) acts by attenuating Mdm2-mediated degradation of p53, thereby stabilizing p53. Recent data indicate that Mdm2 shuttles between the nucleus and the cytoplasm and that nucleo-cytoplasmic shuttling of Mdm2 is essential for Mdm2's ability to promote p53 degradation. Therefore, Mdm2 must export p53 from the nucleus to the cytoplasm where it targets p53 for degradation. We show here that coexpression of p19(ARF) blocks the nucleo-cytoplasmic shuttling of Mdm2. Moreover, subnuclear localization of Mdm2 changes from the nucleoplasm to the nucleolus in a shuttling time-dependent manner, whereas p19(ARF) is exclusively located in the nucleolus. In heterokaryons containing Mdm2 and p19(ARF), the longer the Mdm2 shuttling is allowed, the more Mdm2 protein colocalizes with p19(ARF) in the nucleolus, implying that Mdm2 moves from the nucleoplasm to the nucleolus and then associates with p19(ARF) there. Furthermore, whether or not Mdm2 colocalizes with p19(ARF) in the nucleolus, p19(ARF) prevents Mdm2 shuttling. This observation suggests that Mdm2 might be exported through the nucleolus and p19(ARF) could inhibit the nuclear export of Mdm2 by tethering Mdm2 in the nucleolus. Taken together, p19(ARF) could stabilize p53 by inhibiting the nuclear export of Mdm2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359817      PMCID: PMC22020          DOI: 10.1073/pnas.96.12.6937

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

Review 2.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

Review 3.  The nucleolus.

Authors:  U Scheer; D Weisenberger
Journal:  Curr Opin Cell Biol       Date:  1994-06       Impact factor: 8.382

4.  The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes.

Authors:  V Marechal; B Elenbaas; J Piette; J C Nicolas; A J Levine
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

5.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

6.  Protein-mediated nuclear export of RNA: 5S rRNA containing small RNPs in xenopus oocytes.

Authors:  U Guddat; A H Bakken; T Pieler
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

7.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.

Authors:  W Tao; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

8.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

9.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

10.  Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique.

Authors:  F G Moser; B P Dorman; F H Ruddle
Journal:  J Cell Biol       Date:  1975-09       Impact factor: 10.539

View more
  156 in total

1.  p19ARF targets certain E2F species for degradation.

Authors:  F Martelli; T Hamilton; D P Silver; N E Sharpless; N Bardeesy; M Rokas; R A DePinho; D M Livingston; S R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.

Authors:  A Ito; C H Lai; X Zhao; S Saito; M H Hamilton; E Appella; T P Yao
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

3.  Stress signals utilize multiple pathways to stabilize p53.

Authors:  M Ashcroft; Y Taya; K H Vousden
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

4.  Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60.

Authors:  D Müller; K Thieke; A Bürgin; A Dickmanns; M Eilers
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

5.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

6.  MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

Authors:  E Kobet; X Zeng; Y Zhu; D Keller; H Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 7.  Viruses and apoptosis.

Authors:  B J Thomson
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

8.  ZBP-89 promotes growth arrest through stabilization of p53.

Authors:  L Bai; J L Merchant
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 9.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

10.  Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition.

Authors:  D G Pestov; Z Strezoska; L F Lau
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.